Literature DB >> 16256342

Prognostic relevance of uPAR-del4/5 and TIMP-3 mRNA expression levels in breast cancer.

Matthias Kotzsch1, Juliane Farthmann, Axel Meye, Susanne Fuessel, Gustavo Baretton, Vivianne C G Tjan-Heijnen, Manfred Schmitt, Thomas Luther, Fred C G J Sweep, Viktor Magdolen, Paul N Span.   

Abstract

Recently, two components of important protease systems in cancer, i.e., the urokinase plasminogen activator receptor (uPAR) mRNA splice variant uPAR-del4/5 and the tissue inhibitor of matrix metalloproteinase-3 (TIMP-3), were independently reported to be of prognostic value in breast cancer. In the present study, we have evaluated the impact of both these factors on disease-free survival (DFS) in 205 breast cancer patients by assessing mRNA expression in tumour tissue by quantitative PCR. High uPAR-del4/5 mRNA expression was associated with shorter DFS in breast cancer patients (P=0.0363), whereas high TIMP-3 mRNA levels were associated with a good prognosis (P=0.0049). Furthermore, by combining uPAR-del4/5 with TIMP-3 values, we demonstrate that breast cancer patients with high uPAR-del4/5 and low TIMP-3 mRNA levels had a highly significantly shorter DFS in comparison to those patients with low uPAR-del4/5 and high TIMP-3 mRNA expression (P<0.0001). These patients had a more than 6-fold higher risk for disease recurrence or death in multivariate analysis. Therefore, considering the prognostic impact of two proteolytic factors stemming from complementary protease systems may improve the prediction of disease recurrence in breast cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16256342     DOI: 10.1016/j.ejca.2005.09.002

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  18 in total

1.  uPAR and HER2 Genes Are Usually Co-Amplified in Individual Breast Cancer Cells from Blood and Tissues.

Authors:  Jonathan Uhr
Journal:  Breast Care (Basel)       Date:  2008-10-16       Impact factor: 2.860

2.  Comparative study of the expression of metalloproteases and their inhibitors in different localizations within primary tumours and in metastatic lymph nodes of breast cancer.

Authors:  María Fernanda García; Salomé González-Reyes; Luis Ovidio González; Sara Junquera; Nana Berdize; José Manuel Del Casar; María Medina; Francisco José Vizoso
Journal:  Int J Exp Pathol       Date:  2010-04-20       Impact factor: 1.925

3.  uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues.

Authors:  Songdong Meng; Debu Tripathy; Sanjay Shete; Raheela Ashfaq; Hossein Saboorian; Barbara Haley; Eugene Frenkel; David Euhus; Marilyn Leitch; Cynthia Osborne; Edward Clifford; Steve Perkins; Peter Beitsch; Amanullah Khan; Larry Morrison; Dorothee Herlyn; Leon W M M Terstappen; Nancy Lane; Jianqiang Wang; Jonathan Uhr
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-01       Impact factor: 11.205

Review 4.  "Buy one get one free": armed viruses for the treatment of cancer cells and their microenvironment.

Authors:  Balveen Kaur; Timothy P Cripe; E Antonio Chiocca
Journal:  Curr Gene Ther       Date:  2009-10       Impact factor: 4.391

5.  MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators.

Authors:  Galina Gabriely; Thomas Wurdinger; Santosh Kesari; Christine C Esau; Julja Burchard; Peter S Linsley; Anna M Krichevsky
Journal:  Mol Cell Biol       Date:  2008-06-30       Impact factor: 4.272

6.  Polymorphisms in tissue inhibitors of metalloproteinases-2 and -3 and breast cancer susceptibility and survival.

Authors:  Neeraja B Peterson; Alicia Beeghly-Fadiel; Yu-Tang Gao; Jirong Long; Qiuyin Cai; Xiao-ou Shu; Wei Zheng
Journal:  Int J Cancer       Date:  2009-08-15       Impact factor: 7.396

7.  Inverse association of rab31 and mucin-1 (CA15-3) antigen levels in estrogen receptor-positive (ER+) breast cancer tissues with clinicopathological parameters and patients' prognosis.

Authors:  Matthias Kotzsch; Thomas Kirchner; Susanne Soelch; Sonja Schäfer; Katrin Friedrich; Gustavo Baretton; Viktor Magdolen; Thomas Luther
Journal:  Am J Cancer Res       Date:  2017-09-01       Impact factor: 6.166

Review 8.  Aberrant miRNAs Regulate the Biological Hallmarks of Glioblastoma.

Authors:  Wanli Yu; Sai Liang; Chunzhi Zhang
Journal:  Neuromolecular Med       Date:  2018-09-04       Impact factor: 3.843

9.  Methylation of TIMP3 in esophageal squamous cell carcinoma.

Authors:  Eric Smith; Neville J De Young; Zi-Qiang Tian; Maria Caruso; Andrew R Ruszkiewicz; Jun-Feng Liu; Glyn G Jamieson; Paul A Drew
Journal:  World J Gastroenterol       Date:  2008-01-14       Impact factor: 5.742

10.  miR-21 may acts as an oncomir by targeting RECK, a matrix metalloproteinase regulator, in prostate cancer.

Authors:  Sabrina Thalita Reis; José Pontes-Junior; Alberto Azoubel Antunes; Marcos Francisco Dall'Oglio; Nelson Dip; Carlo Camargo Passerotti; Guilherme Ayres Rossini; Denis Reis Morais; Adriano Joao Nesrallah; Camila Piantino; Miguel Srougi; Katia R Leite
Journal:  BMC Urol       Date:  2012-05-29       Impact factor: 2.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.